![Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial) | The BMJ Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial) | The BMJ](https://www.bmj.com/content/bmj/352/bmj.h6816/F2.large.jpg)
Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial) | The BMJ
![PDF) Long-term prophylactic treatment of attacks of vertigo in Meniére's disease - Comparison of a high with a low dosage of betahistine in an open trial PDF) Long-term prophylactic treatment of attacks of vertigo in Meniére's disease - Comparison of a high with a low dosage of betahistine in an open trial](https://i1.rgstatic.net/publication/5430282_Long-term_prophylactic_treatment_of_attacks_of_vertigo_in_Meniere's_disease_-_Comparison_of_a_high_with_a_low_dosage_of_betahistine_in_an_open_trial/links/57ebc6ad08ae92eb4d2632da/largepreview.png)
PDF) Long-term prophylactic treatment of attacks of vertigo in Meniére's disease - Comparison of a high with a low dosage of betahistine in an open trial
![PDF) Efficacy and safety of betahistine treatment in patients with Meniere's disease: Primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial) PDF) Efficacy and safety of betahistine treatment in patients with Meniere's disease: Primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial)](https://www.researchgate.net/profile/Michael-Strupp/publication/291424748/figure/tbl2/AS:391394075136014@1470327027857/analysis-of-absolute-change-from-baseline-at-month-nine-for-secondary-efficacy_Q320.jpg)